|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- July 25, 2008
CopyrightCOPYRIGHT 2008 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dynavax Technologies Corp., of Berkeley, Calif., said Novartis Vaccines and Diagnostics Inc., an affiliate of Novartis International AG. of Basel, Switzerland, will supply the trivalent influenza vaccine necessary to make Dynavax's Universal Influenza Vaccine. Dynavax's product combines the trivalent vaccine with two conserved influenza antigens and a proprietary second-generation TLR9 agonist. Novartis also gained an exclusive option to negotiate a joint development and commercialization deal with Dynavax after the vaccine completes proof-of-concept trials. Terms were not disclosed.
Emergent BioSolutions Inc., of Rockville, Md., was awarded two grants from the ...
Related newspaper, magazine, and journal articles:
|